Brought to you by 
Sanofi gets rights to Glenmark's TRPV3 antagonists for pain
08 Dec 2015
Executive Summary
Glenmark Pharmaceuticals SA (division of Indian drug company Glenmark Pharmaceuticals Ltd.) has granted Sanofi-Aventis exclusive rights in certain countries to its transient receptor potential vanilloid receptor 3 (TRPV3) antagonists for chronic pain. The deal includes the Phase I candidate GRC15300 for diabetic neuropathic pain and osteoarthritic pain.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi gets rights to Glenmark's TRPV3 antagonists for pain
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice